Sera Prognostics Inc., The Pregnancy Company® , focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that ...
Johnson & Johnson today announced the U.S. Food and Drug Administration (FDA) has approved a new, simplified monthly dosing schedule* for RYBREVANT FASPROtm (amivantamab and hyaluronidase-lpuj). When ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results